Skip to main content
Article thumbnail
Location of Repository

Combination therapy with leflunomide and genetic engineering biological agents

By Nataliya Vladimirovna Chichasova and E L NasonovNatalia Vladimirovna Chichasova and E L Nasonov


The paper gives data on the use of a combination of genetic engineering biological agents (GEBAs) and leflunomide in patients with rheumatoid arthritis (RA). In accordance with the international guidelines, the majority of GEBAs should be given in a combination with methotrexate (MTX), which increases the efficacy of a number of GEBAs (tumor necrosis factor-α inhibitors, rituximab) and affects tolerability (remikeid, humira). However, MTX cannot be always used in real practice. The data given in the paper on the efficiency and safety of the coadministration of leflunomide and a GEBA in patients with active RA, which are based on the results of randomized studies and national registers, including the Russian one, point to the compatibility of the results of treatment with this and GEBA-MTX combinations

Topics: ревматоидный артрит, лефлуномид, метотрексат, генно-инженерные биологические препараты, Medicine, R
Publisher: IMA-PRESS LLC
Year: 2011
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.